Patient-specific neoepitope–MHC class II complex (Neoepitope-MHC II complex)

The patient-specific neoepitope–MHC class II complex is a personalized molecular target formed by the association of a tumor-specific mutant peptide (neoepitope) with the patient's own Major Histocompatibility Complex (MHC) class II molecules (Sahin et al., 2017, Nature). These neoepitopes arise from somatic mutations unique to an individual's tumor, making them highly specific targets that minimize the risk of central tolerance or autoimmunity against healthy tissues (Ott et al., 2017, Nature). While MHC class I complexes typically activate CD8+ cytotoxic T cells, MHC class II complexes are primarily recognized by CD4+ T helper cells, which play a critical role in orchestrating the overall anti-tumor immune response and promoting long-term immunological memory (Alspach et al., 2019, Nature). Therapeutic strategies targeting these complexes include personalized neoantigen vaccines (mRNA, peptide, or DNA-based) and adoptive T-cell therapies using engineered T-cell receptors (TCRs) (Kreiter et al., 2015, Nature). By specifically activating the immune system against these unique markers, clinicians aim to overcome tumor-induced immunosuppression and achieve durable clinical responses in various cancers (Sahin et al., 2017, Nature).

Other names

Tumor-specific neoantigen-MHC II complexNeoantigen-HLA class II complexPersonalized neoepitope-HLA-II complexTSA-MHC II complex

Induction of antigen-specific CD4+ T cell responses through the presentation of tumor-specific mutant peptides on MHC class II molecules, leading to cytokine production and orchestration of a broader anti-tumor immune response (Kreiter et al., 2015, Nature; Alspach et al., 2019, Nature).